A single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in. mice

Simple item page
dc.contributor.authorCespedes, Pablo F.
dc.contributor.authorRey-Jurado, Emma
dc.contributor.authorEspinoza, Janyra A.
dc.contributor.authorRivera, Claudia A.
dc.contributor.authorCanedo-Marroquin, Gisela
dc.contributor.authorBueno, Susan M.
dc.contributor.authorKalergis, Alexis M.
dc.date.accessioned2025-01-23T21:27:01Z
dc.date.available2025-01-23T21:27:01Z
dc.date.issued2017
dc.description.abstractHuman respiratory syncytial virus (hRSV) is a major health burden worldwide, causing the majority of hospitalizations in children under two years old due to bronchiolitis and pneumonia. HRSV causes year-to-year outbreaks of disease, which also affects the elderly and immunocompromised adults. Furthermore, both hRSV morbidity and epidemics are explained by a consistently high rate of re infections that take place throughout the patient life. Although significant efforts have been invested worldwide, currently there are no licensed vaccines to prevent hRSV infection. Here, we describe that a recombinant Bacillus Calmette-Guerin (BCG) vaccine expressing the nucleoprotein (N) of hRSV formulated under current good manufacture practices (cGMP rBCG-N-hRSV) confers protective immunity to the virus in mice. Our results show that a single dose of the GMP rBCG-N-hRSV vaccine retains its capacity to protect mice against a challenge with a disease-causing infection of 1 x 10(7) plaque -forming units (PFUs) of the hRSV A2 clinical strain 13018-8. Compared to unimmunized infected controls, vaccinated mice displayed reduced weight loss and less infiltration of neutrophils within the airways, as well as reduced viral loads in bronchoalveolar lavages, parameters that are characteristic of hRSV infection in mice. Also, ex vivo re-stimulation of splenic T cells at 28 days post-immunization activated a repertoire of T cells secreting IFN-gamma and IL-17, which further suggest that the rBCG-N-hRSV vaccine induced a mixed, CD8(+) and cD4(+) T cell response capable of both restraining viral spread and preventing damage of the lungs. All these features support the notion that rBCG-N-hRSV is a promising candidate vaccine to be used in humans to prevent the disease caused by hRSV in the susceptible population. (C) 2016 Elsevier Ltd. All rights reserved.
dc.fuente.origenWOS
dc.identifier.doi10.1016/j.vaccine.2016.12.048
dc.identifier.eissn1873-2518
dc.identifier.issn0264-410X
dc.identifier.urihttps://doi.org/10.1016/j.vaccine.2016.12.048
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/101370
dc.identifier.wosidWOS:000393257500007
dc.issue.numero5
dc.language.isoen
dc.pagina.final766
dc.pagina.inicio757
dc.revistaVaccine
dc.rightsacceso restringido
dc.subjectHuman respiratory syncytial virus
dc.subjectPulmonary inflammation
dc.subjectViral infection
dc.subjectT cells
dc.subjectTh1
dc.subjectTh17
dc.subjectBacillus Calmette et Guerin
dc.subjectRecombinant vaccine
dc.subject.ods03 Good Health and Well-being
dc.subject.odspa03 Salud y bienestar
dc.titleA single, low dose of a cGMP recombinant BCG vaccine elicits protective T cell immunity against the human respiratory syncytial virus infection and prevents lung pathology in. mice
dc.typeartículo
dc.volumen35
sipa.indexWOS
sipa.trazabilidadWOS;2025-01-12
Files
Collections
Artículos de revistas